Last reviewed · How we verify
Polyethylene Glycol Losenatide
At a glance
| Generic name | Polyethylene Glycol Losenatide |
|---|---|
| Also known as | Comparison before and after treatment |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comprehensive Clinical Evaluation Study of GLP-1RA
- The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: